Skip to main content

Table 1 Baseline characteristics of the patients

From: Effect on sinus cycle length and atrioventricular node function after high-power short-duration versus conventional radiofrequency catheter ablation in paroxysmal atrial fibrillation

Variables

Total (N = 239)

Conventional (N = 198)

HPSD (N = 41)

P value

Age, year

58.6 ± 9.1

58.3 ± 9.3

60.3 ± 8.2

0.198

Male sex

161 (67.4)

133 (67.2)

28 (68.3)

0.889

Height, cm

166.8 ± 9.0

167.0 ± 9.1

165.6 ± 8.2

0.367

Weight, kg

69.5 ± 10.7

69.5 ± 11.0

69.4 ± 9.2

0.964

Body mass index, kg/m2

24.9 ± 2.8

24.9 ± 2.8

25.3 ± 2.9

0.337

Hypertension

86 (36.0)

72 (36.4)

14 (34.1)

0.788

Diabetes mellitus

26 (10.9)

20 (10.1)

6 (14.6)

0.410

Stroke

19 (7.9)

15 (7.6)

4 (9.8)

0.750

Heart failure

5 (2.1)

3 (1.5)

2 (4.9)

0.204

CHA2DS2-VASc

1.3 ± 1.1

1.3 ± 1.1

1.5 ± 1.2

0.177

Coronary artery disease

8 (3.3)

5 (2.5)

3 (7.3)

0.141

Chronic renal insufficiency

13 (5.4)

9 (4.5)

4 (9.8)

0.246

Anticoagulation with NOAC

226 (95.0)

186 (94.4)

40 (97.6)

0.697

B-type natriuretic peptide, pg/mL

73.5 ± 71.8

71.5 ± 72.1

83.3 ± 70.1

0.349

LA diameter, mm

39.3 ± 4.9

39.2 ± 4.9

39.5 ± 4.9

0.676

LV EF, %

61.3 ± 5.3

61.3 ± 4.8

61.0 ± 7.3

0.338

Cavotricuspid isthmus ablation

104 (43.5)

87 (43.9)

17 (41.5)

0.771

  1. Data are presented as mean ± standard deviation or number (%)
  2. HPSD, high power, short duration; LA, left atrium; LV EF, left ventricular ejection fraction; NOAC, non-vitamin K antagonist oral anticoagulant